Working group 2
Pharmacological regulation and drugs
01. Mou included activities
- All the knowledge gathered, and tools developed in WG1 will serve to guide the identification of existing and new compounds that affect (activate or inhibit) NRF2 and influence the course of selected NCDs in cellular and animal models.
- WG2 will strive for standardizing procedures and protocols to maximize the reproducibility of results, and for selecting animal models that are relevant to human disease.
This WG will coordinate all aspects along the pipeline of drug development, including preclinical studies.
02. Mou included tasks
2.1) Inventory of drugs suitable for repurposing as NRF2-based therapeutics.2.2) Inventory of new patented or patentable compounds that activate or inhibit NRF2 and influence the course of various NCDs in cellular and animal models of disease, including electrophiles, PPI inhibitors and NRF2 inhibitors developed by the Action participants.2.3) Coordinate a virtual repository of superior animal models for various NCDs with pathophysiological processes related to NRF2 deregulation, in reciprocal interaction with “Preclinical Trials. EU” organization.2.4) Critical analysis of preclinical results on the above mentioned NRF2-modulators in superior animal models.
This WG will coordinate all aspects along the pipeline of drug development, including preclinical studies.
03. WG members
World wide distribution: 120 participants/ 48 from ITC
04. gender and EXpertise
Balance of WG2
05. specific contribution of the members:
Lorem ipsum
DISEASES MODELS
TOOLS
Activators/ inhibitors
MOLECULAR LEVEL
06. SWOT
Desired outputs from the 1st MC meting
07. Desired outputs
From the 1st MC meeting
08. Main challenges
From the 1st MC meeting
09. HOW WILL we BE CONNECTED?
Slack App
09. HOW WILL we BE CONNECTED?
Slack App
General channels
09. HOW WILL we BE CONNECTED?
Slack App
Add the most relevant bibliography related with NRF2 compounds
09. HOW WILL we BE CONNECTED?
Slack App
Shared databases in Excel files.
10. databases
Shared files in Slack
10. INPUT FOR DATABASES
Searching information from original/review articles
Public compound libraries
NRF2compound inventory
Proprietary compound libraries
Virtual tools/ Bioinformatic support
11. report 1-year
Inventory of repurposing/new NRF2-drugs
- Transform the inventoried information into a review article:
- Free Radical Biology & Medicine (Virtual Special Issue).
- Antioxidants (Special Issues/NRF2 transcription factor).
- Redox Biology
- Schedule the next WG2 online meeting to organize the tasks.
12. Who is able to participate?
Filling the gap
Thank you
Let's continue working!!
Albena Dinkova-Kostova
A.DinkovaKostova@dundee.ac.uk
Ana I Rojo
airojo@iib.uam.es
WG2 presentation
UAM
Created on January 9, 2022
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Higher Education Presentation
View
Psychedelic Presentation
View
Vaporwave presentation
View
Geniaflix Presentation
View
Vintage Mosaic Presentation
View
Modern Zen Presentation
View
Newspaper Presentation
Explore all templates
Transcript
Working group 2
Pharmacological regulation and drugs
01. Mou included activities
This WG will coordinate all aspects along the pipeline of drug development, including preclinical studies.
02. Mou included tasks
2.1) Inventory of drugs suitable for repurposing as NRF2-based therapeutics.2.2) Inventory of new patented or patentable compounds that activate or inhibit NRF2 and influence the course of various NCDs in cellular and animal models of disease, including electrophiles, PPI inhibitors and NRF2 inhibitors developed by the Action participants.2.3) Coordinate a virtual repository of superior animal models for various NCDs with pathophysiological processes related to NRF2 deregulation, in reciprocal interaction with “Preclinical Trials. EU” organization.2.4) Critical analysis of preclinical results on the above mentioned NRF2-modulators in superior animal models.
This WG will coordinate all aspects along the pipeline of drug development, including preclinical studies.
03. WG members
World wide distribution: 120 participants/ 48 from ITC
04. gender and EXpertise
Balance of WG2
05. specific contribution of the members:
Lorem ipsum
DISEASES MODELS
TOOLS
Activators/ inhibitors
MOLECULAR LEVEL
06. SWOT
Desired outputs from the 1st MC meting
07. Desired outputs
From the 1st MC meeting
08. Main challenges
From the 1st MC meeting
09. HOW WILL we BE CONNECTED?
Slack App
09. HOW WILL we BE CONNECTED?
Slack App
General channels
09. HOW WILL we BE CONNECTED?
Slack App
Add the most relevant bibliography related with NRF2 compounds
09. HOW WILL we BE CONNECTED?
Slack App
Shared databases in Excel files.
10. databases
Shared files in Slack
10. INPUT FOR DATABASES
Searching information from original/review articles
Public compound libraries
NRF2compound inventory
Proprietary compound libraries
Virtual tools/ Bioinformatic support
11. report 1-year
Inventory of repurposing/new NRF2-drugs
12. Who is able to participate?
Filling the gap
Thank you
Let's continue working!!
Albena Dinkova-Kostova
A.DinkovaKostova@dundee.ac.uk
Ana I Rojo
airojo@iib.uam.es